Research ExplorerPublicationsSorafenib in advanced hepatocellular carcinoma.

Sorafenib in advanced hepatocellular carcinoma.

Standard

Sorafenib in advanced hepatocellular carcinoma. / Llovet, Josep M; Ricci, Sergio; Mazzaferro, Vincenzo; Hilgard, Philip; Gane, Edward; Blanc, Jean-Frédéric; Oliveira, de; Cosme, Andre; Santoro, Armando; Raoul, Jean-Luc; Forner, Alejandro; Schwartz, Myron; Porta, Camillo; Zeuzem, Stefan; Bolondi, Luigi; Buggisch, Peter; Galle, Peter R; Seitz, Jean-François; Borbath, Ivan; Häussinger, Dieter; Giannaris, Tom; Shan, Minghua; Moscovici, Marius; Voliotis, Dimitris; Bruix, Jordi.

In: NEW ENGL J MED, Vol. 359, No. 4, 4, 2008, p. 378-390.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Llovet, JM, Ricci, S, Mazzaferro, V, Hilgard, P, Gane, E, Blanc, J-F, Oliveira, D, Cosme, A, Santoro, A, Raoul, J-L, Forner, A, Schwartz, M, Porta, C, Zeuzem, S, Bolondi, L, Buggisch, P, Galle, PR, Seitz, J-F, Borbath, I, Häussinger, D, Giannaris, T, Shan, M, Moscovici, M, Voliotis, D & Bruix, J 2008, 'Sorafenib in advanced hepatocellular carcinoma.', NEW ENGL J MED, vol. 359, no. 4, 4, pp. 378-390. <http://www.ncbi.nlm.nih.gov/pubmed/18650514?dopt=Citation>

APA

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J-F., Oliveira, D., Cosme, A., Santoro, A., Raoul, J-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Buggisch, P., Galle, P. R., Seitz, J-F., Borbath, I., ... Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. NEW ENGL J MED, 359(4), 378-390. [4]. http://www.ncbi.nlm.nih.gov/pubmed/18650514?dopt=Citation

Vancouver

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al. Sorafenib in advanced hepatocellular carcinoma. NEW ENGL J MED. 2008;359(4):378-390. 4.

Bibtex

@article{4e40a839953444d78afdacf451d875e5,
title = "Sorafenib in advanced hepatocellular carcinoma.",
abstract = "BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P",
author = "Llovet, {Josep M} and Sergio Ricci and Vincenzo Mazzaferro and Philip Hilgard and Edward Gane and Jean-Fr{\'e}d{\'e}ric Blanc and de Oliveira and Andre Cosme and Armando Santoro and Jean-Luc Raoul and Alejandro Forner and Myron Schwartz and Camillo Porta and Stefan Zeuzem and Luigi Bolondi and Peter Buggisch and Galle, {Peter R} and Jean-Fran{\c c}ois Seitz and Ivan Borbath and Dieter H{\"a}ussinger and Tom Giannaris and Minghua Shan and Marius Moscovici and Dimitris Voliotis and Jordi Bruix",
year = "2008",
language = "Deutsch",
volume = "359",
pages = "378--390",
journal = "NEW ENGL J MED",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

RIS

TY - JOUR

T1 - Sorafenib in advanced hepatocellular carcinoma.

AU - Llovet, Josep M

AU - Ricci, Sergio

AU - Mazzaferro, Vincenzo

AU - Hilgard, Philip

AU - Gane, Edward

AU - Blanc, Jean-Frédéric

AU - Oliveira, de

AU - Cosme, Andre

AU - Santoro, Armando

AU - Raoul, Jean-Luc

AU - Forner, Alejandro

AU - Schwartz, Myron

AU - Porta, Camillo

AU - Zeuzem, Stefan

AU - Bolondi, Luigi

AU - Buggisch, Peter

AU - Galle, Peter R

AU - Seitz, Jean-François

AU - Borbath, Ivan

AU - Häussinger, Dieter

AU - Giannaris, Tom

AU - Shan, Minghua

AU - Moscovici, Marius

AU - Voliotis, Dimitris

AU - Bruix, Jordi

PY - 2008

Y1 - 2008

N2 - BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P

AB - BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P

M3 - SCORING: Zeitschriftenaufsatz

VL - 359

SP - 378

EP - 390

JO - NEW ENGL J MED

JF - NEW ENGL J MED

SN - 0028-4793

IS - 4

M1 - 4

ER -